David Mott | General Partner

David Mott, General Partner, N.E.A.

Dave Mott joined New Enterprise Associates in September 2008 as a General Partner and leads the healthcare investing practice, which typically comprises roughly one-third of each fund, or $1 billion of healthcare venture investments every three years. NEA is a leading investor across all healthcare sub-sectors, including biopharma, medical technology, and healthcare services, and invests across all stages and geographies.  Dave’s personal investing practice is primarily focused on biopharmaceutical investments. Prior to joining NEA, Dave was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in various roles including, from October 2000 through June 2008, president and chief executive officer, and previously chief financial officer, and president and chief operating officer. He led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Prior to joining MedImmune, Dave was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a bachelor of arts degree in economics and government from Dartmouth College. Dave is currently Chairman of 3-V Biosciences, Adaptimmune (NASDAQ: ADAP), Ardelyx (NASDAQ: ARDX), Cydan, Epizyme (NASDAQ: EPZM), Imara, Mersana, and TESARO (NASDAQ: TSRO), and is a director of Clementia (CMTA), Complexa, NightstaRx, and Xtuit.  He has previously been a director of Ambit Pharmaceuticals, Conceptis, Edimer, MedImmune, Omthera Pharmaceuticals, Prosensa, Rib-X Pharmaceuticals, Shire Pharmaceuticals, and Zyngenia.


World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

VC Panel: Investing in the orphan drug space – derisking commercial models and driving biotechs to successful launches

  • Assessing advanced therapies commercial opportunities – and risks – as the new frontier of investment in rare disease companies
  • Type of work and diligence to obtain comfort with the ultimate market opportunity
  • Assessing barriers to entry including therapeutic modality and IP
  • Regulators role in incentivizing or impeding the ability to develop products both domestically and abroad. What can be different?

back to speakers